Tacrolimus and Pentacarinat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tacrolimus (tacrolimus) and Pentacarinat (pentamidine isethionate). Common drug interactions include inflammation among females and stenotrophomonas infection among males.

The phase IV clinical study analyzes what interactions people have when they take Tacrolimus and Pentacarinat. It is created by eHealthMe based on reports of 87 people who take the same drugs from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,161 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 03, 2026

87 people who take Tacrolimus and Pentacarinat together, and have interactions are studied.

Tacrolimus and Pentacarinat drug interactions.

What are the common drug interactions of Tacrolimus and Pentacarinat, by gender? *:

female:

  1. Inflammation
  2. Myalgia (muscle pain)
  3. Venous injury
  4. Wound secretion
  5. Immunosuppressant drug level increased
  6. Abdominal pain
  7. Acute respiratory distress syndrome
  8. Anaemia (lack of blood)
  9. Epstein-barr virus associated lymphoma (epstein-barr virus associated tumour)
  10. Renal failure (kidney dysfunction)

male:

  1. Stenotrophomonas infection
  2. Neutropenia (an abnormally low number of neutrophils)
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  4. Transplant failure (transplantation failed to meet outcome)
  5. Complications of transplanted kidney
  6. Urinary tract infection
  7. Acinetobacter infection (infection by group of bacteria commonly found in soil and water)
  8. Arthralgia (joint pain)
  9. Cardiac failure
  10. Central nervous system lesion (an abnormality in tissue of brain or spinal cord)

What are the common drug interactions of Tacrolimus and Pentacarinat, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Epstein-barr virus associated lymphoproliferative disorder (lymphocytes are produced in excessive quantities associated with epstein-barr virus)
  2. Immunosuppressant drug level increased

10-19:

  1. Pancreatitis acute (sudden inflammation of pancreas)

20-29:

  1. Immunosuppressant drug level increased
  2. Anaemia (lack of blood)
  3. Epstein-barr virus associated lymphoma (epstein-barr virus associated tumour)
  4. Renal failure (kidney dysfunction)
  5. Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)

30-39:

n/a

40-49:

  1. Headache (pain in head)
  2. Inflammation
  3. Myalgia (muscle pain)
  4. Pyrexia (fever)
  5. Febrile neutropenia (fever with reduced white blood cells)

50-59:

  1. Abdominal pain
  2. Acute respiratory distress syndrome
  3. Death
  4. Anaemia (lack of blood)
  5. Anal abscess
  6. Arrhythmia (irregular heartbeat)
  7. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  8. B-lymphocyte abnormalities (abnormal population of b lymphocytes in the blood, bone marrow, or tissues)
  9. Blood parathyroid hormone decreased
  10. Bone marrow necrosis (death of body tissue of bone marrow)

60+:

  1. Stenotrophomonas infection
  2. Neutropenia (an abnormally low number of neutrophils)
  3. Urinary tract infection
  4. Complications of transplanted kidney
  5. Acinetobacter infection (infection by group of bacteria commonly found in soil and water)
  6. Arthralgia (joint pain)
  7. Cardiac failure
  8. Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
  9. Drug level fluctuating
  10. Enterococcal infection

What are the existing conditions these people have? *

  1. High Blood Pressure: 29 people, 33.33%
  2. Lung Transplant Rejection (failure of lung transplant): 21 people, 24.14%
  3. Pain: 20 people, 22.99%
  4. Nausea (feeling of having an urge to vomit): 18 people, 20.69%
  5. Febrile Bone Marrow Aplasia (bone marrow greatly decreases or stops production of blood cells): 18 people, 20.69%
  6. Venoocclusive Disease (small veins in the liver are obstructed): 17 people, 19.54%
  7. Fungal Infection: 17 people, 19.54%
  8. Blood Disorder: 17 people, 19.54%
  9. Abdominal Pain Upper: 17 people, 19.54%
  10. Immunodeficiency Disorders: 14 people, 16.09%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and Pentacarinat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tacrolimus and Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tacrolimus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentacarinat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus and pentamidine isethionate (the active ingredients of Tacrolimus and Pentacarinat, respectively), and Tacrolimus and Pentacarinat (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: